Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with ...

This was the stock's third consecutive day of losses.

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.38 which represents a slight increase of $0.54 or 0.92% from the prior close of $58.84. The stock opened at $58.84 and ...

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session ...

If we earn a $0.63 per share dividend in early January, and then if BMY closes above $60 on January 17, we would be assigned ...

The annualized dividend paid by Bristol Myers Squibb Co. is $2.4/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 10/04/2024 ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual ...